Hemophilia, a hereditary bleeding disorder, arises from a lack of clotting factors—especially Factor VIII—which results in extended bleeding episodes and a heightened risk of joint damage and soft tissue hemorrhages. Conventional systemic therapies necessitate regular intravenous infusions, carry immunogenic risks, and provide limited protection at sites of localized injury. Our goal is to create a biocompatible hydrogel patch that can locally deliver recombinant Factor VIII to improve hemostasis and aid wound healing in hemophilia patients only were it is required. The hydrogel exhibited remarkable porosity, mechanical stability, and a sustained release of biologically active Factor VIII. Compared to the control hydrogels, blood clotting times were considerably shortened, and the localized delivery reduced systemic exposure while ensuring therapeutic efficacy. For hemophilia patients, this hydrogel patch provides a hopeful substitute for systemic infusion therapy, as it allows for targeted and on-demand hemostatic intervention. With its flexible format and inexpensive design, it could serve as a solution for home care, emergency response, and clinical settings with limited resources.